Clinical Trials
281
Active:10
Completed:125
Trial Phases
5 Phases
Early Phase 1:5
Phase 1:84
Phase 2:118
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (257 trials with phase data)β’ Click on a phase to view related trials
Phase 2
118 (45.9%)Phase 1
84 (32.7%)Not Applicable
48 (18.7%)Early Phase 1
5 (1.9%)Phase 3
2 (0.8%)LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
Not Applicable
Recruiting
- Conditions
- Caregiver BurdenColorectal CancerLegal Intervention
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 20
- Registration Number
- NCT07153016
- Locations
- πΊπΈ
Masonic Cancer Center, Minneapolis, Minnesota, United States
UNTOLD Ovarian Cancer Unmet Needs Survey
Recruiting
- Conditions
- Ovarian Cancer
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 2000
- Registration Number
- NCT07070726
- Locations
- πΊπΈ
Masonic Cancer Center, Minneapolis, Minnesota, United States
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 32
- Registration Number
- NCT07008638
- Locations
- πΊπΈ
Masonic Cancer Center, Minneapolis, Minnesota, United States
Allo HSCT for High Risk Hemoglobinopathies
Phase 2
Recruiting
- Conditions
- Graft FailureSickle Cell DiseaseHemoglobinopathies
- Interventions
- Radiation: Total Body IrradiationBiological: Cell Infusion
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 62
- Registration Number
- NCT06872333
- Locations
- πΊπΈ
Masonic Cancer Center, Minneapolis, Minnesota, United States
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Phase 2
Recruiting
- Conditions
- Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 65
- Registration Number
- NCT06792825
- Locations
- πΊπΈ
Masonic Cancer Center, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 57
- Next
News
No news found